Aminolevulinic Acid Hydrochloride and Photodynamic Therapy in Preventing Actinic Keratosis and Non-melanoma Skin Cancer in Patients Who Have Undergone Solid Organ Transplant

Inclusion Criteria

• Received solid organ transplant (kidney or other)
• 3-24 months post-transplant (any number of transplant)
• Time interval of at least 6 days duration where complications such as rejection episodes, viral infections, surgical interventions and therapies with mono or polyclonal antibodies are ruled out by the transplant team
• No prior history of NMSC in the treatment fields
• No actinic keratosis (AK)/Bowen’s disease in the treatment fields within the last 3 months
• Moderate to severe sun damage
• Be willing to forego other interventions in the treatment fields than the ones approved by the investigator that would interfere with the protocol or evaluation of the study medication

Exclusion Criteria

• Patients with Fitzpatrick’s scale skin type IV-VI
• Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins
• Known sensitivity to any of the components of the Levulan Kerastick for topical solution
• Prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit
• Unable to return for follow-up visits and tests
• Any condition or situation which in the investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study